| abstract |
Methods to identify compounds that specifically modulate the interaction of FGFR1 and ß-Klothó are described. The identified compounds may be useful in treating metabolic diseases and disorders that involve the interaction of FGFR1 and ß-Klotho. In various modalities the disease or metabolic disorder is diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. |